| ID Source | ID |
|---|---|
| PubMed CID | 788751 |
| CHEMBL ID | 179024 |
| CHEBI ID | 107780 |
| Synonym |
|---|
| benzoic acid, 2-hydroxy-5-[[(5-methyl-2-furanyl)carbonyl]amino]- |
| 2-hydroxy-5-[(5-methylfuran-2-carbonyl)amino]benzoic acid |
| BIM-0047314.P001 |
| 2-hydroxy-5-[(5-methyl-furan-2-carbonyl)-amino]-benzoic acid |
| OPREA1_291688 |
| 2-hydroxy-5-[(5-methyl-2-furoyl)amino]benzoic acid |
| MLS000061868 |
| smr000070727 |
| CBMICRO_047270 |
| OPREA1_139447 |
| CHEBI:107780 |
| bdbm50158743 |
| AKOS000610306 |
| CHEMBL179024 , |
| HMS2345E17 |
| Q27186113 |
| 2-hydroxy-5-[[(5-methyl-2-furanyl)-oxomethyl]amino]benzoic acid |
| SR-01000529462-1 |
| sr-01000529462 |
| Class | Description |
|---|---|
| furans | Compounds containing at least one furan ring. |
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 28.1838 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 39.8107 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| GLS protein | Homo sapiens (human) | Potency | 12.5893 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 8.9125 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 89.1251 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 31.6228 | 0.0013 | 18.0743 | 39.8107 | AID926 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 35.4813 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 19.9526 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 35.4813 | 0.0401 | 7.4590 | 31.6228 | AID1631; AID1634 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 89.1251 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Vif | Human immunodeficiency virus 1 | IC50 (µMol) | 3.8700 | 0.2700 | 34.0015 | 100.0000 | AID1117319 |
| Tat | Human immunodeficiency virus 1 | IC50 (µMol) | 19.3800 | 0.9960 | 39.8009 | 100.0000 | AID1117361 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | IC50 (µMol) | 3.8700 | 0.2700 | 26.3638 | 100.0000 | AID1117319 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 0.9950 | 10.0000 | AID242127 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 (µMol) | 100.0000 | 0.0001 | 1.0768 | 10.0000 | AID242082; AID242127 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| peroxidase activity | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| prostaglandin-endoperoxide synthase activity | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| protein binding | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| enzyme binding | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| heme binding | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| protein homodimerization activity | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| metal ion binding | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nuclear inner membrane | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| nuclear outer membrane | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| endoplasmic reticulum | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| endoplasmic reticulum lumen | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| caveola | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| neuron projection | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| protein-containing complex | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| neuron projection | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID242082 | Inhibitory concentration against human immuno deficiency virus type 1 integrase (3'-processing) | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. |
| AID242127 | Inhibitory concentration against human immuno deficiency virus type 1 integrase (Strand Transfer) | 2005 | Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1 | Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||